HDAC inhibitors and their potential towards cancer treatment Online publication date: Tue, 21-Jan-2025
by Sanjay Kumar Choubey; Sachin Kumar; Medha Kumari
International Journal of Bioinformatics Research and Applications (IJBRA), Vol. 21, No. 1, 2025
Abstract: Histone deacetylases (HDACs) play a key role in chromatin structure modulation through deacetylation of histones leading to formation of highly compact DNA-histone complex. HDACs have been reported to be implicated in multiple types of cancers. Blocking the activities of histone deacetylases will help to overcome gene repression pressure and it would be possible to check the incessant growth of cells in tumour. Therefore the interest has been developed to design the HDAC inhibitors and their analogues and histone deacetylases are now considered as potential targets for their wide distribution in various forms of cancer. HDAC inhibitors display their role by regulating cyclin dependent kinases (cdK), inducing p21 and various preapoptotic genes like Bax, Bak, repressing the activities of growth factors like VEGF, repressing transcription factor HIF-1α facilitating arrest of cell cycle, modulating various signaling pathways like STAT signaling, AMPK signaling, inducing cell adhesion molecule E-cadherin.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Bioinformatics Research and Applications (IJBRA):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook